Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPC1063 versus Avonex in relapsing multiple sclerosis
NL-OMON42145Phase 3Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ozanimod in multiple sclerosis (MS) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Annualized relapse rate. Planned start Jan 2015; status: withdrawn.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON42145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42145.